References
Morris V, Kennedy E, Baxter N, Benson A III, Cercek A, Cho M, et al. Treatment of metastatic colorectal cancer: ASCO Guideline. J Clin Oncol. 2022;41:678–700.
Nagourney R, Evans S, Tran P, Nagourney A, Sugarbaker P. Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin. Eur J Surg Oncol. 2021;47:738–42.
Quénet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, et al.; UNICANCER-GI Group and BIG Renape Group. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicenter, randomized, open-label, phase 3 trial. Lancet Oncol. 2021;22:256-66.
Verwaal V, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426–32.
https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
I have no any commercial interest that any author may have in the subject of study or the source of any financial or material support.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Jastrzebski, T. Unreliability in the Treatment of Patients with Peritoneal Metastases of Colorectal Cancer in the Current NCCN and ASCO Recommendations. Ann Surg Oncol 30, 3989–3990 (2023). https://doi.org/10.1245/s10434-023-13576-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-023-13576-3